Urinary Incontinence Therapeutics Market Size, Share and Growth Forecast for 2024 - 2031

Urinary Incontinence Therapeutics Market by Type (Urge Incontinence, Overflow Incontinence, Stress Incontinence, and Functional Incontinence,) Drug Class (Anticholinergics, Beta-3 Adrenoceptor Agonists, Alpha Blockers, Estrogen, Desmopressin, and Tricyclic Antidepressants), End User (Hospitals, Retail Pharmacy, & Online Pharmacy) and Region for 2024 to 2031

Urinary Incontinence Therapeutics Market

Industry: Pharmaceuticals

Published Date: September-2024

Format: PPT*, PDF, EXCEL

Delivery Timelines: Contact Sales

Number of Pages: 170

Report Price

$ 4900*

Buy Now
Request Report Sample

Report ID: PMRREP34774

Market Size and Share Analysis

The urinary incontinence therapeutics market is estimated to increase from US$4.4 Bn in 2024 to US$5.8 Bn by 2031. The market is projected to record a CAGR of 4.1% during the forecast period from 2024 to 2031. In 2023, the U.S. urinary incontinence therapeutics market captured a substantial portion of the North America market, driven by the widespread prevalence of the condition, which affects millions of adults.

urinary incontinence therapeutics market size, 2024 - 2031, US$ Bn

Key Highlights of the Market      

  • Innovative therapies including minimally invasive treatments and wearable devices, are enhancing treatment and are expected to drive urinary incontinence therapeutics market.
  • Based on type, stress incontinence segment to account for 40% market share in 2024.
  • Significant growth is expected in regions like North America, Europe, and Asia Pacific, driven by increasing aging population, rising healthcare awareness, and improved access to advanced treatment options.
  • North America is projected to continue maintaining its share of 34% in the market in 2024.
  • Increased public awareness campaigns and funding for incontinence care are boosting market growth further.
  • Retail pharmacy to be the largest contributor accounting for 56% of the Market Share.

Market Attributes

Key Insights

Market Size (2024E)

US$4.4 Bn

Projected Market Value (2031F)

US$5.8 Bn

Global Market Growth Rate (CAGR 2024 to 2031)

4.1%

Historical Market Growth Rate (CAGR 2019 to 2023)

3.8%

North America Urinary Incontinence Therapeutics Market Sets the Stage for Exceptional Growth

Region

Market Share in 2024

North America

34%

North America is projected to lead the urinary retention therapeutics market, capturing 34% of the market share by the end of 2024. This growth is driven by the early adoption of new technologies, a large patient population with urinary disorders, and the easy availability of attractive medical reimbursement options in the U.S. and Canada.

Strategies such as research and development, mergers & acquisitions, and new product launches by leading companies are boosting market growth. For instance, in February 2020, Atlantic Therapeutics announced that the U.S. FDA approved 'INNOVO,' a wearable, non-invasive device for treating stress urinary incontinence in adult women, available over-the-counter. These factors are expected to support the market’s growth in North America.

urinary incontinence therapeutics market, 2024 - 2031

Stress Incontinence to be the Largest Contributor

Category

Market Share in 2024

Type - Stress Incontinence

40%

By type of incontinence, the stress urinary incontinence segment is anticipated to hold a 40% market share by the end of 2024, leading the urine retention therapeutics market. The increase in stress urinary incontinence cases among women is the reason for the surge.

Approximately 50% of women who experience urine incontinence also report having stress incontinence symptoms, according to epidemiological studies on the condition in women. Research has also revealed that after prostate surgery, men's rates of stress urine incontinence vary from 2% to 70%. During the anticipated time, these variables are probably going to drive the segment's expansion.

Retail Pharmacy Spearheads the End User Preferences

Category

Market Share in 2024

End User - Retail Pharmacy

57%

Retail pharmacy dominates the industry accounting for 57% market share in 2024. The retail pharmacies' extensive global reach and established market dominance are a result of their widespread availability and longevity.

Retail pharmacies provide convenience for people looking to purchase UI drugs because they are widely accessible to the public. This accessibility is essential particularly for elderly people who account for a large proportion of patients with incontinence. When patients are managing their use of over-the-counter (OTC) drugs and prescribed therapy, retail pharmacies are frequently their initial point of contact.

Market Introduction and Trend Analysis

The increasing prevalence of urinary incontinence (UI) is due to the factors such as urinary tract infections, weakened pelvic floor muscles, pregnancy, childbirth, and post-surgery in men following prostate removal. These issues are expected to contribute to the rise of UI symptoms and fuel the growth of urinary retention therapies during the forecast period.

The increasing incidence of urological disorders and the development of advanced incontinence devices are projected to boost the urinary retention device market. The demand for minimally invasive procedures, along with an aging population more susceptible to urological issues, is also anticipated to drive market growth.

Many patients with urinary incontinence are shifting from traditional to advanced treatment methods benefiting market expansion. The increasing risk of related urological disorders is expected to further support the market's growth trajectory.

Historical Growth and Course Ahead

The increasing incidence particularly in older adults and post-surgical patients contributed significantly to market expansion. Development of minimally invasive treatments such as neuromodulation devices and botulinum toxin therapies gained traction in the past years. This has significantly contributed to the market's expansion. The market expanded at a CAGR of 3.8%, indicating steady growth during that period.

Development of minimally invasive treatments, such as neuromodulation devices and botulinum toxin therapies gained traction during this period. The market will benefit from a heightened focus on female urinary incontinence with companies investing in new products targeting women.

The urinary incontinence therapeutics market overview has shown consistent growth over the years, and its upward trajectory is expected to continue in the future. The market is projected to capture a CAGR of 4.1% during the forecast period from 2024 to 2031.

Market Growth Drivers

Growing Prostate Cancer Cases

The rising number of prostate cancer cases is boosting the growth of the urinary incontinence therapeutics. market. There is also increasing demand for advanced, minimally invasive over-the-counter (OTC) devices and wearables, which is pushing research and development in urinary retention devices.

Medical technology companies are actively seeking FDA approval for their next-generation devices designed to treat stress incontinence, particularly in women. These developments are expected to fuel market growth in the coming years.

Rising Awareness and Diagnostics Boost Market

Rising awareness about urinary incontinence along with improved diagnostic methods is significantly driving the urinary incontinence therapeutics market. Public health campaigns and educational programs have led to increased knowledge about the condition encouraging more individuals to seek medical help.

With advanced diagnostic tools, healthcare providers can now identify and classify incontinence types more effectively leading to better-targeted treatments. This heightened awareness and diagnosis particularly among old adults and women are increasing the demand for both pharmacological and non-pharmacological therapies contributing to the overall growth of the market.

Factors Impeding the Market

Challenges Limiting Growth

The urinary incontinence therapeutics market faces challenges due to a lack of awareness about new advancements in treatment options and the complications that can arise after using these devices.

The increasing cost of treatment and the vulnerability of the aging population are factors that reduce demand for urinary retention medications. The market's growth is further hindered by patients opting for alternative therapies. Another obstacle is the growing number of people with incontinence who are unaware of their condition, which limits the market's potential expansion during the forecast period.

Increasing Cost of Urinary Incontinence Therapies

The increasing cost of urinary incontinence therapies can make it difficult for patients to afford treatment. As the price of medications and devices rises, some individuals may hesitate to seek help or continue with prescribed treatments. This financial burden can lead to fewer people accessing the necessary care, which impacts their quality of life.

The high expense is a significant barrier preventing them from exploring or sticking with effective therapies, and ultimately limiting their treatment options and market growth for these products.

Future Opportunities for the Urinary Incontinence Therapeutics Market Players

Innovative Product Development in Urinary Incontinence

Innovative product development offers great opportunities for companies in the market. By focusing on new technologies like smart wearables, less invasive treatments, and customized therapies, companies can meet patient needs and stand out from competitors.

Creating advanced solutions with better results and few side effects can boost market growth. Investing in research to develop new products that cater to different patient needs can open new market segments and improve patient satisfaction leading to future success and leadership in the market.

Competitive Landscape for the Urinary Incontinence Therapeutics Market

There are many leading industry players in the fiercely competitive market. To treat urinary retention disease, these players are developing cutting-edge new delivery methods. The market for urinary incontinence therapeutics is anticipated to grow as a result.

Pfizer Inc., AbbVie Inc., Astellas Pharma Inc., Johnson & Johnson,  Viatris Inc., and Teva Pharmaceutical Industries Ltd. are the leading companies in the market. Prominent industry participants tend to employ inorganic growth tactics such as partnerships, acquisitions, mergers, and collaborations to enhance their range of products. The global market for urinary retention therapies is expected to benefit from this.

Recent Developments in the Urinary Incontinence Therapeutics Market

  • In March 2024, Sumitomo Pharma America announced that the FDA had accepted a supplemental new drug application for vibegron. This application aims to gain approval for treating men with overactive bladder (OAB) symptoms who are already receiving pharmacological treatment for benign prostatic hyperplasia (BPH).
  • In April 2024, Zydus Lifesciences launched a generic drug for overactive bladder in the US, targeting symptoms like urge urinary incontinence, urgency, and urinary frequency. The medication will be manufactured at Zydus group's formulation facility in India.

Urinary Incontinence Therapeutics Industry Report Scope

Attributes

Details

Forecast Period

2024 to 2031

Historical Data Available for

2019 to 2023

Market Analysis

US$ Billion for Value

Key Regions Covered

  • North America
  • Europe
  • East Asia
  • South Asia & Oceania
  • Latin America
  • The Middle East & Africa

Key Market Segments Covered

  • By Type  
  • By Drug Class
  • By End User
  • By Region

Key Companies Profiled

  • Pfizer Inc.
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Johnson & Johnson
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A.
  • GlaxoSmithKline plc
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Bayer AG
  • Ferring Pharmaceuticals
  • Others

Report Coverage

  • Market Forecast
  • Company Share Analysis
  • Competition Intelligence
  • DROT Analysis
  • Market Dynamics and Challenges
  • Strategic Growth Initiatives

Customization & Pricing

Available upon request

Urinary Incontinence Therapeutics Industry Segmentation

By Type

  • Urge Incontinence
  • Overflow Incontinence
  • Stress Incontinence
  • Functional Incontinence
  • Other

By Drug Class

  • Anticholinergics
  • Beta-3 Adrenoceptor Agonists
  • Alpha Blockers
  • Estrogen
  • Desmopressin
  • Tricyclic Antidepressants
  • Other

By End User

  • Hospitals
  • Retail Pharmacy
  • Online Pharmacy

By Region

  • North America
  • Europe
  • East Asia
  • South Asia & Oceania
  • Latin America
  • The Middle East & Africa

To know more about delivery timeline for this report Contact Sales

Companies Covered in This Report

  • Pfizer Inc.
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Johnson & Johnson
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A.
  • GlaxoSmithKline plc
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Bayer AG
  • Ferring Pharmaceuticals
  • Others

Frequently Asked Questions

The market is estimated to increase from US$4.4 Bn in 2024 to US$5.8 Bn by 2031.

Rising awareness and diagnosis rates is a key driver for market growth.

A few of the key market players are Pfizer Inc., AbbVie Inc., Astellas Pharma Inc., Johnson & Johnson, Viatris Inc.

The market is projected to record a CAGR of 4.1% during the forecast period from 2024 to 2031.

Shift towards personalized medicine in the urinary incontinence therapeutics industry presents a significant opportunity.

Thank you for taking time to visit our website, click like if you found the information on this page useful?

This site uses cookies, including third-party cookies, that help us to provide and improve our services.
Google translate